Abstract: Disclosed are compounds of Formula (I) wherein: one of A and D is —N— and the other of A and D is —C—; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function of glucocorticoid receptor activity and pharmaceutical compositions comprising such compounds.

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract: A control system for an engine that includes a turbocharger includes a restriction estimation module and an engine protection module. The restriction estimation module estimates restriction of airflow through an air filter of the engine based on a comparison between measured and modeled temperatures at an outlet of a compressor of the turbocharger. The engine protection module, based on the estimated airflow restriction, at least one of controls turbocharger boost, controls turbocharger airflow, controls a fueling rate of the engine, and generates a warning signal for a driver of a vehicle.

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I):, its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (Rx)(Ry); is heterocyclo or heteroaryl; E is —N—, —NR1—, —O—, —C(?O), —S—, —SO2—, or —CR2—; F is —N—, —NR1a, —O—, —C(?O), —S—, —SO2—, or —CR2a—; G is independently N, —NR1b—, —O—, —C(?O), —S—, —SO2— or —CR2b— provided that the heterocyclic ring formed does not contain a S—S or S—O bond and at least one of E, F and G is a hetero atom; and Ma, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, R4, R5a, R6, R7, X, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases employing said compounds.

Abstract: A method of diagnosing operation of a turbo speed sensor that monitors a turbocharger in an internal combustion engine system includes determining whether the engine system is operating in one of a high speed and a low speed range and determining a threshold turbo speed value based on whether engine system is operating in one of the high speed and the low speed range. An actual turbo speed value of the turbocharger is monitored based on a signal generated by the turbo speed sensor. The actual turbo speed value is compared to the threshold turbo speed value and a diagnostic signal is generated based on the step of comparing.

Abstract: An intake throttle valve (ITV) position determination module generates a desired ITV position based on at least one of a desired airflow in a regeneration mode and an exhaust braking request in an exhaust braking mode. An ITV position limitation module generates a limited ITV position based on the desired ITV position. A transition module detects a transition from the exhaust braking mode to the regeneration mode, wherein an ITV is controlled to the limited ITV position after the transition is detected.

Abstract: An intake control system comprises an estimation module and a turbocharger control module. The estimation module receives one of a first pressure within an intake manifold measured by a manifold pressure sensor and a second pressure measured by a pressure sensor at a location between a compressed air charge cooler and a throttle valve. The estimation module estimates the other one of the first and second pressures based on the received one of the first and second pressures. The turbocharger control module controls output of a turbocharger based on the estimate of the other one of the first and second pressures.

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (Rx)(Ry); is heterocyclo or heteroaryl; E is —N—, —NR1—, —O—, —C(?O), —S—, —SO2—, or —CR2—; F is —N—, —NR1a, —O—, —C(?O), —S—, —SO2—, or —CR2a—; G is independently N, —NR1b—, —O—, —C(?O), —S—, —SO2— or —CR2b— provided that the heterocyclic ring formed does not contain a S—S or S—O bond and at least one of E, F and G is a hetero atom; and Ma, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, R4, R5a, R6, R7, X, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases employing said compounds.

Abstract: An engine control system comprises a current control module and a solenoid actuator module. The current control module determines a duty cycle based on a desired current through a solenoid of an engine system and a resistance of the solenoid and corrects the resistance based on an actual current through the solenoid. The solenoid actuator module actuates the solenoid based on the duty cycle.

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract: An engine control module includes a power module and a turbine temperature module. The power module controls engine power output based on a turbine temperature. The turbine temperature module determines the turbine temperature based on a turbine inlet temperature. The power module decreases the engine power output when the turbine temperature is greater than or equal to a predetermined threshold temperature.

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR1—, —O—, —S—, —SO2— or —CR2—; F is —N—, —NR1a—, —O—, —S—, —SO2— or —CR2a—; G is N, —NR1b—, —O—, —S—, —SO2— or —CR2b—, provided that the E-F-G containing heterocyclic ring formed does not contain a S—S or S—O bond, and at least one of E, F and G is a heteroatom; J, Ja, M, Ma, Q, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, and R3 to R21, Z, Za, Zb, and Zc are as defined above.

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

Abstract: A method of a digital photo frame (DPF) with television (TV) tuning function is provided. The method includes: creating one or more preview windows on the DPF under the DPF mode; receiving broadcasts of particular channels; displaying the broadcast contents of the particular channels in each of the preview windows; switching the DPF to a TV mode if a mode switching signal is received within the display of the broadcast contents of the particular channels; determining which of favorite channels currently previewed in the preview windows is selected; and receiving and playing broadcasts of the selected particular channel. A related DPF is also provided.

Abstract: A control system comprising a current control module and a force control module. The current control module selectively supplies a current to a turbine bypass valve (TBV) to adjust the TBV to a predetermined position. The force control module selectively adjusts the current in response to a determination that an actual TBV position is less than a predetermined distance from the predetermined position.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Abstract: A method used in a digital photo frame (DPF) for automatically entering and switching operational mode is provided. In an exemplary embodiment, the method includes: obtaining TV program information from a TV program table under a DPF mode; determining whether a TV program is on or about to start at the current time; automatically entering a TV mode or switching from the DPF mode to the TV mode when a TV program is on or about to start; and automatically receiving and playing the TV program.

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract: An intake throttle valve (ITV) position determination module generates a desired ITV position based on at least one of a desired airflow in a regeneration mode and an exhaust braking request in an exhaust braking mode. An ITV position limitation module generates a limited ITV position based on the desired ITV position. A transition module detects a transition from the exhaust braking mode to the regeneration mode, wherein an ITV is controlled to the limited ITV position after the transition is detected.

Abstract: An exhaust gas recirculation control system comprises a pressure condition evaluation module and a protection module. The pressure condition evaluation module evaluates at least one of vane movement of a turbocharger and engine pressure. The protection module selectively controls an exhaust gas recirculation valve based on the at least one of the vane movement of the turbocharger and the engine pressure.